Changes in Ectopic Fat Following Surgically Induced Weight Loss



Status:Completed
Conditions:Obesity Weight Loss, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:12/15/2017
Start Date:August 2008
End Date:December 2012

Use our guide to learn which trials are right for you!

Changes in Ectopic Fat Following Surgically Induced Weight Loss: Does it Explain the Resolution of Diabetes?

This study evaluates how ectopic fat (in the pancreas, heart, liver and skeletal muscle),
visceral fat, and subcutaneous fat changes following surgically induced weight loss using
gastric banding. The investigators also evaluate whether changes in pancreatic fat content
correlate with improvement in beta-cell function.

We are looking for volunteers for this study,wich involves 7 visits over a period of 13
months, the first visit taking place about 2 weeks prior to the planned surgery.

Visit 1 - baseline, before starting your pre-operative diet Visit 2 - just before the surgery
Visit 3 - around the time your first band inflation occurs Visit 4 - 1 month after the band
inflation Visit 5 - 3 months after the first band inflation Visit 6 - 6 months after the
first band inflation Visit 7 - 12 months after the first band inflation

At each visit we do the following tests:

1. MRS to measure your fat in the liver, pancreas, heart, muscle (leg), subcutaneous fat
and visceral fat.

2. Frequently sampled intravenous glucose tolerance test - it is a 3.5 hrs test which
determines the amount of insulin your body produces and how well your own insulin is
being used by the body

3. Body measurements (waist, hip circumference), cholesterol panel, liver function tests,
HbA1c (to monitor diabetes control), blood pressure, weight.

We also do an oral glucose tolerance test to check for diabetes on 3 occasions: visit 1,
visit 5 and at the end, visit 7.

Inclusion Criteria:

- Greater than 18 years old

- Fully understanding and willing to undergo study procedures

- Available for follow-up

- Understand and willing to sign informed consent

- Pharmacologic agents with the potential to change ectopic fat content (i.e.
pioglitazone) are allowed if the patient has been on a stable dose for at least 3
months and plans to continue the same dose for the duration of the study

Exclusion Criteria:

- Contraindication to MRI (i.e. metallic implants, severe claustrophobia, weight above
320lb)

- Contraindication to phlebotomy (i.e. no accessible veins, hemoglobin <10 mg/dL)

- History of pancreatic disease other than diabetes

- Regular use of more than 2 alcoholic drinks per day

- Pregnancy

- Non-English speaking
We found this trial at
1
site
Dallas, Texas 75390
?
mi
from
Dallas, TX
Click here to add this to my saved trials